MetaCap

Tyra Biosciences (TYRA) vs UroGen Pharma (URGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

UroGen Pharma (URGN) has outperformed Tyra Biosciences (TYRA) over the past year, gaining 6.9% versus a loss of 4.7%. Over five years, URGN leads with a +127.8% price change compared with -15.7% for TYRA. Tyra Biosciences is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TYRA-4.73%URGN+6.88%
+101%+30%-41%
Nov 21, 20251 yearNov 20, 2026
TYRA-16.17%URGN+129.27%
+319%+111%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TYRA versus URGN key metrics
MetricTYRAURGN
Share price$20.12$27.65
Market cap$1.39B$1.36B
1-day change+1.98%-12.86%
YTD return-23.47%+18.06%
1-year return-4.73%+6.88%
5-year return-15.71%+127.76%
Forward P/E—11.08
EPS (TTM)$-2.63$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$109.79M
Revenue growth (YoY)—+21.45%
Net income (latest FY)$-119.95M$-153.49M
Gross margin—88.66%
Operating margin—-113.73%
Net margin—-139.81%
52-week high$40.65$50.81
52-week low$18.25$16.50
Distance from 52-week high-50.50%-45.58%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+135.83%+119.57%
Average volume852.56K1.11M
Shares outstanding69.08M49.05M
Employees87300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • URGN has outperformed TYRA by 11.6 percentage points over the past year.

About Tyra Biosciences

TYRA stock →

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About UroGen Pharma

URGN stock →

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees

TYRA vs URGN FAQ

Which is bigger, Tyra Biosciences or UroGen Pharma?

Tyra Biosciences (TYRA) is larger, with a market capitalization of $1.39B compared with $1.36B for UroGen Pharma (URGN).

Which stock has performed better over the past year, TYRA or URGN?

URGN returned +6.88% over the past 12 months, compared with -4.73% for TYRA (price return, excluding dividends). Past performance does not predict future results.

Are Tyra Biosciences and UroGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons